Teva Pharmaceuticals — full event log
Every event we have on file across every reporting year. The Data-by-year tab summarises the top 10 per year; this page shows them all.
← back to Data by year2024· 18 events
On December 5, 2024, Teva announced agreement to sell its Japan business venture (51% stake in Teva-Takeda) to JKI Co. Ltd. for completion by April 1, 2025. Generic and legacy products. Classified as held for sale at year-end 2024.
sustainability_report p.4
On January 31, 2024, Teva announced intent to divest its API business (R&D, manufacturing and commercial activities) through a sale, in alignment with Pivot to Growth strategy. Classified as held for sale at year-end 2024. Recorded $1,280M goodwill impairment and $275M impairment on classification as held for sale.
sustainability_report p.11
Teva references validated Science-Based Targets for GHG reductions. Sustainability-linked senior notes include performance targets on absolute greenhouse gas emissions reduction and improving access to medicines in low- and middle-income countries.
sustainability_report p.48
Teva has issued sustainability-linked senior notes with targets that include improving access to medicines in low- and middle-income countries and reducing GHG emissions. Failure to achieve targets results in interest rate step-ups of 0.10%-0.375% or one-time premium payments.
sustainability_report p.49
Teva expects to first have to disclose pursuant to EU's Corporate Sustainability Reporting Directive (CSRD) in accordance with European Sustainability Reporting Standards (ESRS) in 2026, including double materiality assessments.
sustainability_report p.50
Effective January 1, 2024, Canada is reported as part of the International Markets segment and the North America segment was renamed United States segment. Prior periods were recast.
sustainability_report p.3
Teva continued implementation of its global EHS management system in 2024 across all countries of operation, with proactive compliance evaluation, EHS leading indicators, and continued promotion of a climate change mitigation and adaptation strategy according to international standards. Water management is being addressed with a scarcity-focused approach to conservation.
sustainability_report p.15
Teva implemented a supplier audit program to ensure suppliers meet quality and operational standards. The Company sources APIs from its own facilities plus suppliers in Europe, Asia and the Americas, and continues to strengthen its third-party operations unit to meet cost, supply security and quality targets sustainably.
sustainability_report p.14
In November 2024, the EU adopted revisions to the Urban Wastewater Treatment Directive requiring pharmaceutical companies to pay for a majority of the costs to remove micropollutants from wastewater. This represents a new product stewardship cost lever extending Teva's environmental responsibility downstream into water treatment infrastructure.
sustainability_report p.48
On December 5, 2024, Teva announced agreement with JKI Co. Ltd. to sell Teva-Takeda generics/legacy business venture in Japan. Expected closing April 1, 2025. Resulted in ~$690M expected loss including FX translation adjustments.
sustainability_report p.4
As part of the Pivot to Growth strategy, Teva is optimizing global generics portfolio through product discontinuation and cost-structure improvements, including closure or divestment of a significant number of manufacturing plants in recent years across the United States, Europe, Israel, Japan and India. This network consolidation reduces operational footprint and energy use across 34 finished dosage plants in 27 countries.
sustainability_report p.14
Teva is placing increased attention on water management, implementing a scarcity-focused approach to water conservation to align with community needs and advance toward sustainable operations. Risk management addresses extreme weather events including floods, heatwaves, hurricanes, sea level rise and water stress.
sustainability_report p.49
Teva operates 34 finished dosage and packaging plants in 27 countries and 13 API production facilities, and has closed or divested a significant number of manufacturing plants in recent years as part of network optimization under the Pivot to Growth strategy. The classification of the API business and Japan business as held for sale further reduces operated emissions scope.
sustainability_report p.14
Teva implemented a supplier audit program for its ~13 API production facilities and external suppliers in Europe, Asia and the Americas to ensure suppliers meet quality and ESG standards. The Company maintains multiple supply sources for APIs and strengthens its third-party operations unit to meet cost, supply security and quality targets sustainably.
sustainability_report p.14
On January 31, 2024, Teva announced intent to divest its API business (including R&D, manufacturing and commercial activities) through a sale, in alignment with Pivot to Growth strategy. Classified as held for sale Dec 31, 2024 with $275M expected loss.
sustainability_report p.11
On June 23, 2024, Teva entered agreement with ITA to settle litigation for taxable years 2008-2020, with total payment of ~$750M over six years. Resulted in $506M increase in 2024 income taxes.
sustainability_report p.158
Teva continued implementation of its global EHS management system in all countries where it operates, promoting proactive compliance, establishing EHS standards across global operations and driving continuous improvement. Teva continues to promote climate change mitigation and adaptation strategy according to international standards, with validated Science-Based Targets for GHG reductions.
sustainability_report p.15
Teva recorded goodwill impairment charges of $1,280M in 2024 related to API reporting unit, driven by Pivot to Growth strategy assumptions and intention to divest API business. Compared to $700M impairment in 2023 for International Markets reporting unit.
sustainability_report p.60
2023· 2 events
In June 2023, Teva consummated nationwide opioids settlement with states/subdivisions. Will pay up to $4.25 billion over 13 years including up to $1.2 billion of generic Narcan supply. 100% of US states and litigating subdivisions and Native American tribes have settled.
sustainability_report p.150
In May 2023, Teva announced Pivot to Growth strategy with four pillars: deliver on growth engines (AUSTEDO, AJOVY, UZEDY), step up innovation, sustain generic medicines powerhouse, and focus business by optimizing portfolio and manufacturing footprint.
sustainability_report p.5
2021· 1 event
Teva issued sustainability-linked senior notes tied to absolute GHG emissions reduction and access to medicines in low/middle-income countries. Coupon step-up of 0.1-0.45% if targets missed. References validated Science-Based Targets.
sustainability_report p.49